Overview
Canadian Drug
Approval Process
Accomplishments
National Myeloma
Database
Collaborating
Centres
Overview
Real-World Evidence (RWE) refers to data collected from routine clinical practice, including electronic health records, patient registries, and patient-reported outcomes. For CMRG, RWE is essential to understanding how multiple myeloma therapies perform across diverse populations, assessing long-term outcomes, and identifying safety signals beyond clinical trials. By leveraging national real-world data, CMRG helps inform clinical practice, guide policy and regulatory decisions, and optimize treatment strategies to improve patient outcomes.
Canadian Drug Approval Process
In Canada, the drug approval process is primarily governed by Health Canada, which evaluates the safety, efficacy, and quality of new medications through rigorous clinical trials. However, Real World Evidence (RWE) is increasingly playing a pivotal role in complementing this traditional framework, especially in the post-approval phase.
While clinical trials are essential for understanding how a drug performs under controlled conditions, RWE offers insights into how medications work in broader, more diverse patient populations after the drug is already on the market. Here’s how RWE contributes to the Canadian approval and regulatory process:
Post-Market Surveillance:
After a drug is approved, RWE is used to monitor its safety and efficacy in real-world settings. This ongoing surveillance helps identify rare or long-term side effects that may not have been apparent during clinical trials.
Health Technology Assessment (HTA):
Organizations like CADTH utilize RWE to inform Health Technology Assessments, which guide provincial and territorial drug reimbursement decisions. This ensures that new therapies are not only effective but also offer value for the healthcare system.
Regulatory Decision-Making:
RWE can support regulatory decisions by providing additional data on the drug’s effectiveness in everyday clinical practice. For instance, Health Canada and the Canadian Agency for Drugs and Technologies in Health (CADTH) may rely on RWE to reassess drug indications or expand the use of a drug to other patient populations based on real-world outcomes.
Bridging Evidence Gaps:
RWE can provide data where clinical trials are lacking, such as in specific patient subgroups (e.g., elderly, those with comorbidities). This allows regulators to make more informed decisions about a drug’s use in real-world scenarios.
Patient-Centric Insights:
RWE captures patient-reported outcomes, treatment adherence, and quality of life metrics, which are increasingly important to regulators. This data helps assess the practical benefits and risks of treatments, providing a more comprehensive view of their impact on patients’ daily lives.
As RWE continues to grow in importance, it helps enhance patient safety, improve drug access, and ensure that treatments remain effective in everyday medical practice across Canada
Accomplishments
National Myeloma Database Overview
The Canadian Myeloma Research Group National Database (CMRG-ND) is a vital tool for advancing real-world evidence (RWE) research in multiple myeloma. By capturing data from a broad spectrum of patients across Canada, the CMRG-ND allows for the analysis of real-world treatment practices, patient outcomes, and disease progression outside of controlled clinical trials. This data is critical in evaluating how therapies perform in diverse patient populations, including those with comorbidities, older age, or other factors that might exclude them from clinical trials.
The database gathers comprehensive patient information, including demographics, disease characteristics, treatment histories, and long-term outcomes, which helps researchers identify trends and patterns in care. This real-world evidence informs not only clinical practice but also regulatory and policy decisions, guiding the approval of new therapies and refining treatment guidelines. Through this platform, the CMRG-ND accelerates the generation of meaningful insights that directly impact patient care, contribute to personalized medicine, and shape future innovations in multiple myeloma treatment.
Collaborating Centres
The CMRG National Database reflects the strength of a highly collaborative national network, with 25+ contributing centres across Canada working together to advance robust real-world evidence in multiple myeloma. This broad participation highlights a shared commitment and a positive culture of cooperation across provinces and care settings.
Among the top contributing centres (listed alphabetically) are:
- BC Cancer
- CancerCare Manitoba
- Centre hospitalier de l’Université de Montréal (CHUM)
- Hamilton Health Sciences
- Hôpital Maisonneuve-Rosemont
- London Health Sciences Centre
- Nova Scotia Health Authority
- Princess Margaret Cancer Centre
- Queen Elizabeth II Health Sciences Centre
- Saskatchewan Cancer Agency
- The Ottawa Hospital
- Tom Baker Cancer Centre
Together, these and other participating institutions exemplify the depth, positivity, and pan-Canadian collaboration that underpin the impact and credibility of the CMRG National Database.